CHMP recommends EU approval of Roche's Polivy combination fo

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma over the standard of care in... | March 25, 2022

Related Keywords

Portugal , Japan , Lugano , Ticino , Switzerland , United States , France , Belgium , America , Polatuzumab Vedotin , Nathalie Meetz , Sileia Urech , Levi Garraway , Loren Kalm , Karsten Kleine , Genentech , European Commission , World Health Organization , Head Of Global Product Development , Lymphoma Study Association , Roche Group , Roche Group Media Relations , Lymphoma Academic Research Organisation , European Medicines Agency , Medicinal Products , Human Use , Chief Medical Officer , Global Product , England Journal , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Cancer Incidence , Previously Untreated Diffuse Largeb Cell , Roche Holding Ag Stock Exchange , News , Information , Press Release , Polivy , Plus , Howed , First , Linically , Meaningful , Improvement , N , Ifs , Ith , Comparable , Safety , People , Reviously , Untreated , Diffuse , Barge , Lymphoma , Dover , The , Standard , F , Are Rog Ch0012032048 ,